Khanh Pham, MD
Urology · Bellevue, WANPI 1538331665
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (54.5%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. 37 manufacturers reported payments, led by Verathon Inc. at 54.5% of the total. Reporting peaked in 2023 at $4,853 and has fallen 64.0% since, to $1,746 in 2025.
Across 126 payments — averaging $80.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Verathon Inc.$6K
- Procept Biorobotics Corporation$1K
- Sumitomo Pharma America, Inc.$503
- Cook Medical LLC$326
- Olympus America Inc.$314
- Boston Scientific$311
- plus $2K from 31 others
What the payments were for
- Consulting fees$5,50055%
- Travel & lodging$3163%
- Food & beverage$4,21342%
- Education$581%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Verathon Inc. | 3 | $5,500 |
| Procept Biorobotics Corporation | 13 | $1,127 |
| Sumitomo Pharma America, Inc. | 15 | $503 |
| Cook Medical LLC | 3 | $326 |
| Olympus America Inc. | 5 | $314 |
| Boston Scientific | 9 | $311 |
| Astellas Pharma US Inc | 10 | $258 |
| Intuitive Surgical | 3 | $219 |
| Antares Pharma, Inc. | 7 | $129 |
| Dornier Medtech America, Inc | 1 | $124 |
| Myriad Genetic Laboratories, Inc. | 5 | $123 |
| 180 Medical, Inc. | 4 | $112 |
| Convatec Inc. | 4 | $95 |
| Urovant Sciences Inc | 3 | $85 |
| Therapeuticsmd, Inc. | 4 | $84 |
| Ferring Pharmaceuticals Inc. | 3 | $73 |
| Progenics Pharmaceuticals, Inc. | 3 | $73 |
| Bayer | 3 | $62 |
| Johnson & Johnson | 2 | $55 |
| Coloplast | 3 | $55 |
| Rochester Medical Corporation | 3 | $51 |
| Urogen Pharma, Inc. | 1 | $42 |
| Zyla Life Sciences, Inc. | 3 | $38 |
| C. R. Bard, Inc. & Subsidiaries | 1 | $38 |
| Baxter Healthcare | 2 | $36 |
| AbbVie | 1 | $34 |
| Ambu Inc. | 1 | $29 |
| Pfizer | 2 | $28 |
| Endo USA, Inc. | 1 | $27 |
| Laborie Medical Technologies Corp. | 1 | $23 |
| Abbott | 1 | $19 |
| Profound Medical Corp. | 1 | $18 |
| Smith+Nephew | 1 | $17 |
| BD | 1 | $16 |
| Medtronic | 1 | $15 |
| AMAG Pharmaceuticals, Inc. | 1 | $14 |
| Endo Pharmaceuticals Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NPD Clinical Study$5,500
- AquaBeam Robotic System$760
- LITHO 150$188
- Da Vinci Surgical System$157
- GEMTESA$145
- Dornier MedTech$124
- Cook$118
- AQUABEAM SYSTEM$111
How this compares
$10,087 in reported general payments places this provider in the 85th percentile of 274 urology providers in Washington.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 69 | $70,198 |
| GemtesaVibegron | 14 | $14,221 |
| Tamsulosin Hcl | 242 | $4,602 |
| Finasteride | 116 | $2,365 |
| Silodosin | 26 | $1,988 |
| Solifenacin Succinate | 32 | $1,131 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 17 | $551 |
| Oxybutynin Chloride ErOxybutynin Chloride | 22 | $318 |
| Ciprofloxacin Hcl | 50 | $163 |
| Cephalexin | 19 | $140 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 33 | $109 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 14 | $61 |
| Oxycodone Hcl | 19 | $53 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq | $258 | $70,19869 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $503 | $14,22114 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 274 urology providers in Washington.
Other urology in Bellevue
- James PorterSeattle$471K
- Marah HehemannSeattle$213K
- Raymond LanceSpokane$211K
- Thomas WalshSeattle$186K
- Alvaro LucioniSeattle$148K
- Una LeeSeattle$116K
- George SchadeSeattle$78K
- Kevin OstrowskiKirkland$64K
- Marco SalazarEdmonds$58K
- Anthony BuiVancouver$55K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.